Buffett’s Berkshire exited Merck investment just before COVID pill boost, further trimmed AbbVie and BMS holdingsnews2021-11-16T13:14:05+00:00November 16th, 2021|Fierce Pharma|
List Bio to build new $125M microbiome plant in Indiana, hire 210news2021-11-16T13:00:50+00:00November 16th, 2021|Fierce Pharma|
Pfizer, like Merck, inks deal to license COVID-19 pill and boost global supplynews2021-11-16T11:50:21+00:00November 16th, 2021|Fierce Pharma|
AbbVie re-ups University of Chicago cancer pact, extending alliance out to 2025 after drug delivery progressnews2021-11-16T11:47:36+00:00November 16th, 2021|Fierce Pharma|
Inovio clears up queries about delivery of COVID-19 vaccine, prompting FDA to lift clinical hold news2021-11-16T11:44:39+00:00November 16th, 2021|Fierce Pharma|
AHA: J&J’s Invokana chases AZ’s Farxiga and Lilly’s Jardiance with phase 3 heart failure winnews2021-11-15T19:54:22+00:00November 15th, 2021|Fierce Pharma|
AHA: Eli Lilly and Boehringer Ingelheim’s Jardiance stays on its heart failure winning streak—this time in acute patientsnews2021-11-15T19:09:42+00:00November 15th, 2021|Fierce Pharma|
Thermo Fisher will build lab supply plant in North Carolina as part of $193M federal contractnews2021-11-15T17:33:47+00:00November 15th, 2021|Fierce Pharma|
BioMarin’s new launch Voxzogo could surprise investors and become a blockbuster brand: analystnews2021-11-15T15:27:42+00:00November 15th, 2021|Fierce Pharma|
Apellis’ eye med application on track for next year after FDA OKs inclusion of phase 2 datanews2021-11-15T14:56:10+00:00November 15th, 2021|Fierce Pharma|
